Sponsor Overview
Explore verified public information about Bayer's expanded access programs, compassionate use policies, and patient eligibility pathways. This report aggregates official statements, independent research, and regulatory data to help patients, providers, and sponsors collaborate efficiently.
Unique references curated across 4 content categories.
ClinicalTrials.gov data sources power this status.
Dataset refreshed continuously through Right2Hope ETL pipelines.
Expanded Access Intelligence
Official Statements
Score contribution: 100 — 1 supporting sources.
“You may be able to access an investigational medicine either by participating in a clinical trial or, in exceptional cases, through single patient access (sometimes referred to as “compassionate use”).”
Active EAPs on ClinicalTrials.gov
Score contribution: 60 — 1 supporting sources.
Conditions: Advanced Non-small Cell Lung Cancer, Cancer
Past EAPs on ClinicalTrials.gov
Score contribution: 40 — 9 supporting sources.
Conditions: Solid Tumors Harboring NTRK Fusion
Conditions: Gastrointestinal Stromal Tumors
Conditions: Tumors Harboring NTRK Fusion
Conditions: Colorectal Neoplasms
Conditions: Prostatic Neoplasms
Conditions: Hypertension, Pulmonary
Reagan-Udall Foundation Insights
Single-Patient EA Policies/Criteria If your doctor believes that an investigational medicine could help you but you cannot take part in a clinical trial, it might still be possible to access the treatment. Single patient access may not be allowed in some countries, so please check your local regulations to find out. This is only possible in exceptional circumstances when you, or someone you’re caring for, are suffering from a severely debilitating or life-threatening disease that cannot be treated with available approved drugs, or where all possible approved treatments have been unsuccessful. At this point, your doctor might consider an investigational treatment as the only way to help. We will let your doctor know we have received the application within two working days. Once we have all the information we need, we will do our best to complete our assessment and get back to your doctor within five working days. We can only agree to provide an investigational medicine to your doctor if we agree with their medical evaluation that the possible benefits of the drug outweigh the potential risks. We take care to ensure that we comply with the laws that apply in different countries for investigational medicines and treatments. We also work together with doctors to ensure that they comply with local laws regarding access to investigational medicines, including monitoring and recording patient safety information. We consider every request for access carefully, but we cannot guarantee that it will be granted.
Partner with Right2Hope
Right2Hope helps sponsors translate regulatory programs into actionable patient access pathways. Connect with our team to publish new programs, streamline intake workflows, or align with providers seeking compassionate use options.